Eric Barta, individually and on behalf of all others similarly situated v. Novo Nordisk A/S, Maziar Mike Doustdar, Lars Fruergaard Jørgensen, Karsten Munk Knudsen, and David S. Moore

CourtDistrict Court, D. New Jersey
DecidedFebruary 17, 2026
Docket3:25-cv-14045
StatusUnknown

This text of Eric Barta, individually and on behalf of all others similarly situated v. Novo Nordisk A/S, Maziar Mike Doustdar, Lars Fruergaard Jørgensen, Karsten Munk Knudsen, and David S. Moore (Eric Barta, individually and on behalf of all others similarly situated v. Novo Nordisk A/S, Maziar Mike Doustdar, Lars Fruergaard Jørgensen, Karsten Munk Knudsen, and David S. Moore) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Eric Barta, individually and on behalf of all others similarly situated v. Novo Nordisk A/S, Maziar Mike Doustdar, Lars Fruergaard Jørgensen, Karsten Munk Knudsen, and David S. Moore, (D.N.J. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

ERIC BARTA, individually and on Civ. No. 25-14045 (ZNQ)(JBD) behalf of all others similarly situated, MEMORANDUM ORDER Plaintiff,

v.

NOVO NORDISK A/S, MAZIAR MIKE DOUSTDAR, LARS FRUERGAARD JØRGENSEN, KARSTEN MUNK KNUDSEN, and DAVID S. MOORE,

Defendants.

Before the Court are three competing motions to appoint lead plaintiff in this putative securities class action lawsuit. The first motion is by IAM Motor City Pension Fund; the second is by Ahmed Hashim; and the last is by Roman Ivanov. [Dkts. 4, 5, 7.] The Court has reviewed each motion and enters this non-dispositive order pursuant to 15 U.S.C. § 78u-4(a)(3)(B), Local Civil Rule 72.1, and 28 U.S.C. § 636. For the reasons set forth below, the Court appoints Ahmed Hashim as lead plaintiff and Levi & Korsinsky, LLP as lead counsel. * On August 1, 2025, plaintiff Eric Barta brought a putative securities class action on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo”) common stock between May 7, 2025 and July 28, 2025 against Novo and several of its current and former executives, seeking monetary damages pursuant to §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 (“PSLRA”), and Rule 10b-5, 17 C.F.R. § 240.10b-5. [Dkt. 1] at 2, 5-6. In brief, the complaint alleges that defendants made materially false and

misleading statements concerning Novo’s expected sales and revenue growth for the 2025 fiscal year, including statements concerning Novo’s ability to grow GLP-1 sales, the overall potential of the GLP-1 market, and more. [Dkt. 1] at 2-3. According to the complaint, defendants concealed material adverse facts that caused investors to purchase Novo stock at artificially inflated prices. [Dkt. 1] at 3. As a result, the complaint alleges that the investors suffered losses after Novo’s

stock price fell from $69.00 per share to $53.94 on July 29, 2025 once these adverse facts were publicly disclosed. [Dkt. 1] at 4. After Barta filed the complaint on behalf of Novo investors, three members of the putative class, IAM Motor City Pension Fund (“the Fund”), Ahmed Hashim,1 and Roman Ivanov filed competing motions to be appointed as lead plaintiff and to have their selected counsel approved as lead counsel. [Dkts. 4, 5, 7.] *

The PSLRA directs courts to “appoint as lead plaintiff the member or members of the purported plaintiff class that the court determines to be most capable of adequately representing the interests of the class members . . . .” 15 U.S.C. § 78u-4(a)(3)(B)(i). The statute creates a rebuttable presumption that the most adequate plaintiff is the person or group of persons that: (1) “has either filed

1 Levi & Korsinsky, LLP filed the complaint on behalf of plaintiff Barta. That firm also represents movant Hashim. the complaint or made a motion in response to a notice” advising members of the purported plaintiff class of the action; (2) “has the largest financial interest in the relief sought by the class; and” (3) “otherwise satisfies the requirements of Rule 23

of the Federal Rules of Civil Procedure.” 15 U.S.C. §78u-4(a)(3)(B)(iii)(I). The presumption may be rebutted by evidence that shows that the presumptively most adequate plaintiff (1) “will not fairly or adequately protect the interests of the class; or” (2) “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” 15 U.S.C. §78u-4(a)(3)(B)(iii)(II). *

As an initial matter, the PSLRA requires the plaintiff who files the initial action to publish a notice to the class within 20 days of filing the complaint informing class members of (i) the pendency of the action; (ii) the claims asserted in the complaint; (iii) the class period; and (iv) their right to seek appointment as lead plaintiff. 15 U.S.C. § 78u-4(a)(3)(A)(i). Within 60 days of publishing that notice, any putative class member may move to serve as lead plaintiff. Id. § 78u- 4(a)(3)(A)(i)(II). This Court “has an independent duty to scrutinize the published

notice and ensure that the notice comports with the objectives of the PSLRA, that is, encouraging the most adequate plaintiff, . . . to come forward and take control of the litigation.” California Pub. Emps. Retirement Sys. v. Chubb Corp., 127 F. Supp. 2d 572, 577 (D.N.J. 2001) (citations omitted). Here, in compliance with the PSLRA, Levi & Korsinsky (plaintiff Barta’s and movant Hashim’s counsel) published a detailed notice of this suit in Globe Newswire within 20 days of filing the complaint. The notice informed putative class members of the pendency of the action, the claims asserted against defendants, the class period, and their right to request to serve as lead plaintiff by filing a motion no later

than September 30, 2025. [Dkts. 4-3, 5-6, 7-3.] Following the notice, all three movants timely filed their motion for appointment as lead plaintiff. [Dkts. 4, 5, 7.] The Court is satisfied that adequate notice was provided pursuant to the statute. Accordingly, the Court next determines which movant is the presumptive lead plaintiff, and whether any member of the putative class has rebutted that presumption. In re Cendant Corp. Litig., 264 F.3d 201, 262 (3d Cir. 2001) (citing

15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)-(II). * The Court’s analysis in identifying the presumptive lead plaintiff “begins with the identification of the movant with ‘the largest financial interest in the relief sought by the class.’” Id. (quoting 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(bb)). In determining which movant has the largest financial interest, courts consider: “(1) the number of shares that the movant purchased during the putative class

period; (2) the total net funds expended by the plaintiffs during the class period; and (3) the approximate losses suffered by the plaintiffs.” Cendant, 264 F.3d at 262 (citations omitted). The third factor is afforded the greatest weight in identifying the presumptive lead plaintiff. See Roby v. Ocean Power Techs, Inc., Civ. Nos. 14- 3799, 14-3815, 14-4015, and 14-4592 (FLW), 2015 WL 1334320, at *5 (D.N.J. Mar. 17, 2015) (collecting cases).2 In this case, the putative class period is from May 7, 2025 through July 28,

2025. According to its motion papers, during that time, the Fund acquired 3,619 shares of Novo stock at a total cost of $248,777.25. [Dkt. 4-4.] The Fund asserts that it has suffered a loss of $52,317 resulting from the difference between the amount it paid for the shares ($248,777.25) and the proceeds ($196,459.43) from selling all 3,619 shares at an average price of $54.29. [Dkt.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
California Public Employees' Retirement System v. Chubb Corp.
127 F. Supp. 2d 572 (D. New Jersey, 2001)
In re Party City Securities Litigation
189 F.R.D. 91 (D. New Jersey, 1999)
In re Milestone Scientific Securities Litigation
183 F.R.D. 404 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Eric Barta, individually and on behalf of all others similarly situated v. Novo Nordisk A/S, Maziar Mike Doustdar, Lars Fruergaard Jørgensen, Karsten Munk Knudsen, and David S. Moore, Counsel Stack Legal Research, https://law.counselstack.com/opinion/eric-barta-individually-and-on-behalf-of-all-others-similarly-situated-v-njd-2026.